Psyence Biomedical Settles Shareholder Litigation with KAOS Capital for $1.5M and Share Buyout
PBM sits 15% above its 52-week low of $2.535 on light trading volume (0.2× avg).
Summary
Psyence Biomedical Ltd. has reached a settlement with activist shareholder KAOS Capital, agreeing to pay $1.5 million and facilitate the sale of KAOS's 50,220 shares at a premium to resolve ongoing litigation and shareholder claims.
Key Events · Legal and Risk Events · PBM
-
Settlement Reached
Psyence Biomedical Ltd. settled a direct shareholder claim and related litigation with KAOS Capital Ltd. and Adam Arviv, resolving a dispute that began in January 2026.
-
Significant Cash Payment
The company agreed to pay KAOS Capital $1,500,000 USD in full and final settlement of all claims, a substantial financial commitment for the company.
-
Share Disposition at Premium
KAOS Capital will sell its entire holding of 50,220 common shares to a company-designated third party at $5.00 USD per share, which is a premium compared to the current market price of $2.92.
-
Litigation Resolved and Standstill Agreement
The settlement includes a full retraction of KAOS's allegations, a mutual release of claims, and a three-year standstill agreement preventing further activist actions by the KAOS Group.
Analysis · PBM · Life Sciences
This settlement is a critical development for Psyence Biomedical, resolving a contentious shareholder dispute with KAOS Capital that involved litigation and allegations against the company. While the $1.5 million cash payment represents a substantial outflow for a company of this size, it removes significant legal and operational uncertainty. The agreement also includes the sale of KAOS's entire stake at a premium to the current market price, effectively removing an activist investor and securing a three-year standstill agreement, which should bring greater corporate stability. This follows a series of recent filings related to shareholder meetings and a reverse stock split, indicating a period of corporate restructuring and governance challenges. Investors should monitor the company's cash position and how this settlement impacts its operational runway.
At the time of this filing, PBM was trading at $2.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $2.54 to $74.94. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.